Douglas Lankler - Pfizer Executive Vice President General Counsel

PFE Stock  USD 27.78  0.19  0.69%   

President

Mr. Douglas M. Lankler is the Executive Vice President, General Counsel of Pfizer Inc. Mr. Lankler was corporate Secretary from January 2014 until February 2014. Executive Vice President, Chief Compliance and Risk Officer from February 2011 until December 2013. Executive Vice President, Chief Compliance Officer from December 2010 until February 2011. Senior Vice President and Chief Compliance Officer from January 2010 until December 2010. Senior Vice President, Deputy General Counsel and Chief Compliance Officer from August 2009 until January 2010. Senior Vice President, Associate General Counsel and Chief Compliance Officer from October 2006 until August 2009. since 2014.
Age 58
Tenure 10 years
Address 66 Hudson Boulevard East, New York, NY, United States, 10001-2192
Phone212 733 2323
Webhttps://www.pfizer.com

Pfizer Management Efficiency

The company has Return on Asset of 0.0155 % which means that on every $100 spent on assets, it made $0.0155 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0235 %, implying that it generated $0.0235 on every 100 dollars invested. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities. As of March 28, 2024, Return On Capital Employed is expected to decline to 0.02. In addition to that, Return On Assets is expected to decline to 0.01. At present, Pfizer's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 9.7 B, whereas Total Current Assets are forecasted to decline to about 32.2 B.
The company has 75.04 B in debt with debt to equity (D/E) ratio of 0.4, which is OK given its current industry classification. Pfizer Inc has a current ratio of 1.56, which is typical for the industry and considered as normal. Debt can assist Pfizer until it has trouble settling it off, either with new capital or with free cash flow. So, Pfizer's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pfizer Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pfizer to invest in growth at high rates of return. When we think about Pfizer's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Marcus ChapmanSeres Therapeutics
47
Michael TangAgilent Technologies
50
Alicia RodriguezAgilent Technologies
N/A
Dominique GrauAgilent Technologies
65
Patrick KaltenbachAgilent Technologies
53
Michele TrucksisSeres Therapeutics
64
Rodney GonsalvesAgilent Technologies
58
Craig PhilipsKineta Inc
63
Jacob ThaysenAgilent Technologies
49
Thomas DesRosierSeres Therapeutics
63
Wendy RiederMadrigal Pharmaceuticals
46
Marc SchneebaumMadrigal Pharmaceuticals
64
Henrik AncherJensenAgilent Technologies
59
Samraat RahaAgilent Technologies
51
Bruce SteelEquillium
50
Bruce CFAEquillium
58
Wael HashadSeres Therapeutics
N/A
Kevin HorganSeres Therapeutics
58
Robert McMahonAgilent Technologies
55
Rebecca TaubMadrigal Pharmaceuticals
66
Mark DoakAgilent Technologies
63
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 79000 people. Pfizer Inc (PFE) is traded on New York Stock Exchange in USA. It is located in 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 and employs 88,000 people. Pfizer is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Pfizer Inc Leadership Team

Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller
Douglas Lankler, Executive Vice President General Counsel
Shantanu Narayen, Lead Independent Director
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical
Susan DesmondHellmann, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer
Aamir Malik, Executive Vice President Chief Business Innovation Officer
Christopher Stevo, Senior Vice President and Chief Investor Relations Officer
Geno Germano, Group President of Global Innovative Pharma Bus.
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
William Carapezzi, Executive Vice President - Global Business Services and Transformation
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President
Mikael MD, Chief Development
Payal Becher, Chief VP
James Quincey, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Payal Sahni, Executive Vice President, Chief People Experience Officer
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President - Pfizer Biopharmaceuticals Group
Mike Mcdermott, Executive Vice President Chief Global Supply Officer
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
John Young, Group President - Pfizer Innovative Health and Angela Hwang
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
James Smith, Independent Director
Christopher CFA, VP Officer
Dennis Ausiello, Independent Director
Michael Mcdermott, Executive Vice President Chief Global Supply Officer
Francesca DeMartino, Chief Officer
Frances Fergusson, Independent Director
Gordon Loh, Senior Vice President Corporate Audit
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
David Denton, Chief VP
Alexander Mackenzie, Executive Vice President Chief Development Officer
DVM DVM, Chairman CEO
William Gray, Independent Director
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Susan Hockfield, Independent Director
Freda LewisHall, Executive Vice President Chief Medical Officer
Albert DVM, Chairman CEO
Dan Littman, Independent Director
Ian Read, Chairman, CEO and Chairman of Executive Committee
James Kilts, Independent Director
Don Cornwell, Independent Director
Andreas Panayiotou, Global Officer
Joseph Echevarria, Independent Director
Scott Gottlieb, Independent Director
Ronald Blaylock, Independent Director
Michael Goettler, Group President - Pfizer Upjohn

Pfizer Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pfizer Investors Sentiment

The influence of Pfizer's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Pfizer. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Pfizer's public news can be used to forecast risks associated with an investment in Pfizer. The trend in average sentiment can be used to explain how an investor holding Pfizer can time the market purely based on public headlines and social activities around Pfizer Inc. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Pfizer's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Pfizer's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Pfizer's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Pfizer.

Pfizer Implied Volatility

    
  52.55  
Pfizer's implied volatility exposes the market's sentiment of Pfizer Inc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Pfizer's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Pfizer stock will not fluctuate a lot when Pfizer's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pfizer in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pfizer's short interest history, or implied volatility extrapolated from Pfizer options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census.
Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.

Complementary Tools for Pfizer Stock analysis

When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Money Managers
Screen money managers from public funds and ETFs managed around the world
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.76)
Dividend Share
1.64
Earnings Share
0.37
Revenue Per Share
10.366
Quarterly Revenue Growth
(0.41)
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.